EQS Equasens Société anonyme
Equasens Société anonyme provides healthcare IT solutions in France, Italy, Belgium, Germany, the United Kingdom, and internationally. The company operates through Sales of Configurations and Hardware, Maintenance Services and Subscriptions, and Software and Services segments. The company engages in publishing and distribution of pharmacy, practice, management software and related offerings for pharmacies, medical-social establishments, doctors, and medical auxiliaries; distribution of computer equipment, turnkey installation and training; after-sales services, and telephone support and maintenance; and data backup, intermediation, and vocational training services. It also provides medical remote monitoring systems, develops a structured medical speech recognition solution, and designs and manufactures connected electronic devices and equipment, as well as offers interoperability solutions. In addition, the company offers financing platform to facilitate multi-donor management, and financing solutions for leased assets for healthcare professionals and others. It serves healthcare facilities and healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-lès-Nancy, France. Equasens Société anonyme operates as a subsidiary of Marque Verte Sante.…
Industry Peers
Health Information ServicesKey Statistics
About Equasens (EPA: EQS)
›
Equasens (EPA: EQS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 1,500 employees.
The shares were at 26.45 EUR on 19 November 2026, down 35.9% over 52 weeks. Its 52-week range is 25.55 EUR to 45.35 EUR: the price is 41.7% below the high and 3.5% above the low.
At a market capitalisation of 397.55M EUR, it trades at 9.9 times trailing earnings and 8.1 times forward earnings. The median trailing P/E of its 14 largest Health Information Services peers is 42.1, a discount of 76% for EQS. It pays a dividend yielding 5.08% (it pays out 48% of its earnings).
Equasens reports return on equity of 15.6%, an operating margin of 20.5% and revenue up 7.4% year over year.
Its debt exceeds its cash by 1.72M EUR, a debt-to-equity ratio of 0.24. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock; their mean price target of 51.80 EUR is 95.8% above the current price. The next earnings report is expected on 1 April 2027.